Pulmonary aspergillosis in a patient with rheumatoid arthritis treated by etanercept.
Lassoued
S
S
Sire
S
S
Farny
M
M
Billey
T
T
Lassoued
K
K
D000935:Antifungal Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000209:etiology / Q000473:pathology / Q000628:therapy; D004322:Drainage; D000068800:Etanercept; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008875:Middle Aged; D011030:Pneumothorax; D011743:Pyrimidines / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D011743:Pyrimidines; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014230:Triazoles; D065819:Voriconazole; D000068800:Etanercept